The "Ophthalmics Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering. Fully revised and updated, the report provides details of 344 ophthalmics ...

DALLAS, June 26, 2025 /PRNewswire/ -- Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering severe ...

Key takeaways: ST-100 achieved statistically significant week 1 improvements in fluorescein staining and visual function. Stuart Therapeutics is planning to conduct an additional clinical trial.

Nektar Therapeutics (NASDAQ: NKTR) stock is up around 150% in today’s trading session following the recently announced positive results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin ...

Nektar Therapeutics shares doubled in early trading Tuesday after the U.S. biotech firm said it reached its targets in a midstage study of its eczema treatment.

STUART, Fla., June 24, 2025 /PRNewswire/ -- Stuart Therapeutics, Inc., a clinical-stage drug platform company developing novel therapies for ophthalmic diseases, today announced the initial ...

Stuart Therapeutics’ dry eye disease drug has failed to demonstrate it can increase tear production in a phase 3 test.

Stuart Therapeutics announces initial results of phase III clinical trial for ST-100 (vezocolmitide) ophthalmic solution, a novel dry eye disease candidate. News release.

The self-driving taxis feature a “Robotaxi” logo written out in a graffiti style on the car’s front doors. The scrawled typeface is reminiscent of the branding for the video game Cyberpunk ...